(193 days)
Not Found
No
The 510(k) summary describes a physical medical device (a micro catheter) and its mechanical and material properties. There is no mention of software, algorithms, or data processing that would suggest the use of AI or ML.
Yes
The device is intended for drug infusion in intra-arterial therapy and embolic materials for hemostasis, which are therapeutic applications.
No
The device is an infusion micro catheter designed to facilitate the delivery of substances (contrast media, drugs, embolic materials) into vessels. It is not described as analyzing or interpreting data to provide a diagnosis.
No
The device description clearly details a physical catheter with specific dimensions, materials (stainless steel wire, lubricious material, hydrophilic coating), and packaging. It is a hardware medical device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for facilitating the infusion of substances (contrast media, drugs, embolic materials) into the body, specifically into blood vessels. This is an in vivo application, meaning it's used within a living organism.
- Device Description: The description details a catheter designed for insertion into blood vessels to deliver substances. This aligns with an in vivo medical device.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue) in vitro (outside the body) to provide information for diagnostic purposes.
IVD devices are used to perform tests on samples taken from the body to diagnose diseases or conditions. This device is used to deliver substances directly into the body for diagnostic imaging (with contrast media) or therapeutic purposes (drug infusion, embolization).
N/A
Intended Use / Indications for Use
The FluidiTube® 2.7F Infusion Micro Catheter is intended to facilitate infusion of contrast media into all peripheral vessels up to and including the cervical vessels, all vessels in the lower and upper extremities, visceral vessels and all coronary vessels. It is also intended for drug infusion in intra-arterial therapy and embolic materials for hemostasis. The FluidiTube® 2.7F Infusion Micro Catheter is not to be used in cerebral blood vessels.
Product codes
KRA
Device Description
The FluidiTube® 2.7F Infusion Micro Catheter is a tapered 2.7F/2.9F single lumen catheter with a luer lock hub designed to facilitate the access of distal vasculature over a guidewire. The FluidiTube® has a semi-rigid proximal shaft that becomes progressively more flexible towards the distal end. The shaft is reinforced with braided stainless steel wire for kink resistance. The inner lumen is lined with a lubricious material to facilitate the movement of a guidewire. The outer surface of the catheter has a hydrophilic coating that becomes lubricious when wet with saline or blood. The FluidiTube® catheter is introduced to the target location through a guiding catheter 0.038" (0.97 mm) or larger and is compatible with 0.021" (0.53 mm) guidewires or smaller. Device configurations consist of one profile size (2.7F) with two different usable lengths (110cm, 130cm). The final device is packaged in a Tyvek pouch and sterilized by ethylene oxide (EO). The device is for single use only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
all peripheral vessels up to and including the cervical vessels, all vessels in the lower and upper extremities, visceral vessels and all coronary vessels. Not to be used in cerebral blood vessels.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical testing was not conducted to evaluate substantial equivalence. Usability testing was conducted in an animal model under a simulated use environment to validate the performance of the device. Callisyn FluidiTube® 2.7F Infusion Micro Catheters were compared to Progreat® 2.7 F Microcatheters in a healthy male Yorkshire swine. Operators successfully tracked the microcatheters into the right artery, the hepatic arteries, and the contralateral iliac artery, and injected the representative diagnostic (non-ionic contrast media Omnipaque 300), therapeutic (Heparin), and embolic material (embolic microspheres 500-700μm) through each microcatheter into the hepatic arteries as required by the protocol. Both Operators rated all test and control microcatheters as acceptable for:
- . Ability to flush the packaging hoop and remove the microcatheter from the hoop without damage
- Ability to track the microcatheter through all three vessels and visualize them ● fluoroscopically
- Compatibility with the guidewire (0.014 in the RCA, 0.021 in the hepatic . artery, and 0.018 in the iliac artery)
- . Ability to visualize the device under fluoroscopy
- Compatibility 1mL of heparin, 2mL of non-dilute contrast media, and 1mL of ● 500-700um embolic microspheres when injected into the hepatic artery
- Integrity, with no kinking or damage to the tip ●
There was no damage to the catheters noted, no vascular dissection was observed, and no thrombus was observed on any catheter when removed from the animal.
After a thorough assessment of all test article performance features, including use in conjunction with common ancillary diagnostic and therapeutic products, both Operators determined that all study protocol specified acute performance requirements of the FluidiTube® were successfully met for this study and it is comparable to the Terumo Progreat® 2.7Fr Microcatheters predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1210 Continuous flush catheter.
(a)
Identification. A continuous flush catheter is an attachment to a catheter-transducer system that permits continuous intravascular flushing at a slow infusion rate for the purpose of eliminating clotting, back-leakage, and waveform damping.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing right, resembling a bird in flight.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 27, 2017
Callisyn Biomedical, Inc. % Gordon MacFarlane Regulatory Project Manager Icon 62 Forest Street. Suite 300 Marlborough, Massachusetts 01752
Re: K161967
Trade/Device Name: FluidiTube 2.7F Infusion Micro Catheter, 110 cm and 130 cm Regulation Number: 21 CFR 870.1210 Regulation Name: Continuous Flush Catheter Regulatory Class: Class II Product Code: KRA Dated: December 28, 2016 Received: December 29, 2016
Dear Gordon MacFarlane:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Fernando Agnel
Fernando Aguel-S
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
4. INDICATIONS FOR USE
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
Indications for Use
See PRA Statement below.
| 510(k) Number (if known) | K161967 |
|---|---|
| Device Name | FluidiTube® 2.7F Infusion Micro Catheter |
Indications for Use (Describe)
The FluidiTube® 2.7F Infusion Micro Catheter is intended to facilitate infusion of contrast media into all peripheral vessels up to and including the cervical vessels, all vessels in the lower and upper extremities, visceral vessels and all coronary vessels. It is also intended for drug infusion in intra-arterial therapy and embolic materials for hemostasis. The FluidiTube® 2.7F Infusion Micro Catheter is not to be used in cerebral blood vessels.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 7.9 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
5. 510(K) SUMMARY
510(k) Summary for the Callisyn FluidiTube 2.7F Infusion Micro Catheter
(per 21CFR 807.92 and http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/default.htm)
1. SUBMITTER/510(K) HOLDER
Callisyn Biomedical, Inc. 260 Candlestick Road North Andover, MA 01845
| Contact: | Shallwei Sun, General Manager |
|---|---|
| Contact's Phone: | +1 (978)-687-0596 |
| Contact's Email: | Shallwei0@yahoo.com |
| Date Prepared: | July 14, 2016 |
2. DEVICE NAME
| Trade Name: | Callisyn FluidiTube® 2.7F Infusion Micro Catheter |
|---|---|
| Classification Name: | Continuous flush catheter |
| Classification Panel: | Cardiovascular |
| Classification Regulation: | 21 CFR 870.1210 |
| Product Code: | KRA |
| Class: | II |
3. PREDICATE DEVICE
- Progreat®, manufactured by Terumo Medical Corporation, K033913 ●
4. DEVICE DESCRIPTION
The FluidiTube® 2.7F Infusion Micro Catheter is a tapered 2.7F/2.9F single lumen catheter with a luer lock hub designed to facilitate the access of distal vasculature over a guidewire. The FluidiTube® has a semi-rigid proximal shaft that becomes progressively more flexible towards the distal end. The shaft is reinforced with braided stainless steel wire for kink resistance. The inner lumen is lined with a lubricious material to facilitate the movement of a guidewire. The outer surface of the catheter has a hydrophilic coating that becomes lubricious when wet with saline or blood. The FluidiTube® catheter is introduced to the target location through a guiding catheter 0.038" (0.97 mm) or larger and is compatible with 0.021" (0.53 mm) guidewires or smaller.
4
Device configurations consist of one profile size (2.7F) with two different usable lengths (110cm, 130cm). The final device is packaged in a Tyvek pouch and sterilized by ethylene oxide (EO). The device is for single use only.
5. INDICATION FOR USE/INTENDED USE
The FluidiTube® 2.7F Infusion Micro Catheter is intended to facilitate infusion of contrast media into all peripheral vessels up to and including the cervical vessels, all vessels in the lower and upper extremities, visceral vessels and all coronary vessels. It is also intended for drug infusion in intra-arterial therapy and embolic materials for hemostasis.
The FluidiTube® 2.7F Infusion Micro Catheter is not to be used in cerebral blood vessels.
6. SUMMARY OF TECHNOLOGICAL CHARACTERISTICS COMPARED TO THE PREDICATE DEVICE
A summary comparison of technological characteristics, including design and materials is provided in the table below:
| Feature | FluidiTube® 2.7F Infusion Micro Catheter | Progreat® |
|---|---|---|
| (Callisyn Biomedical, Inc.) | (Terumo Medical Corporation) | |
| Regulatory Status | Subject Device | K033913 |
| Indications for Use | The FluidiTube® 2.7F Infusion Micro Catheter is | |
| intended to facilitate infusion of contrast media | ||
| into all peripheral vessels up to and including the | ||
| cervical vessels, all vessels in the lower and upper | ||
| extremities, visceral vessels and all coronary | ||
| vessels. It is also intended for drug infusion in | ||
| intra-arterial therapy and embolic materials for | ||
| hemostasis. | ||
| The FluidiTube® 2.7F Infusion Micro Catheter is | ||
| not to be used in cerebral blood vessels. | The Progreat® is intended for the infusion of | |
| contrast media into all peripheral vessels up to and | ||
| including the cervical vessels, all vessels in the | ||
| lower and upper extremities, visceral vessels, and | ||
| all coronary vessels. The Progreat is also intended | ||
| for drug infusion in intra-arterial therapy and the | ||
| infusion of embolic materials for hemostasis in | ||
| procedures including but not limited to Uterine | ||
| Fibroid Embolization. The Progreat should not be | ||
| used in cerebral vessels. | ||
| Hydrophilic | ||
| Coating | Yes | Yes |
| Working Length | 110cm and 130cm | 100 - 150cm |
| Radiopaque | ||
| Marker | Yes | Yes |
| Dimensions | Outer diameter distal: 2.7F, 0.90mm | |
| Outer diameter proximal: 2.9F, 0.97mm | ||
| Inner diameter: 0.025in, 0.65mm | Outer diameter distal: 2.7F, 0.90mm | |
| Outer diameter proximal: 2.9F, 0.97mm | ||
| Inner diameter: 0.025in, 0.65mm | ||
| Strain Relief and | ||
| Hub | Yes | Yes |
| Guidewire | ||
| Compatibility | 0.021" (0.53mm) or smaller | 0.021" (0.53mm) or smaller |
| Guiding Catheter | ||
| Compatibility | 0.038" (0.97mm) or bigger | 0.038" (0.97mm) or bigger |
| Sterile | Yes (Ethylene Oxide) | Yes (Ethylene Oxide) |
| Single Use | Yes | Yes |
Callisyn Biomedical, Inc., Traditional 510(k) July 14, 2016
5
The FluidiTube® 2.7F Infusion Micro Catheter submitted in this 510(k) is substantially equivalent in intended use, design, technology/principles of operation, materials, and performance to the Progreat Catheter K033913. Differences between the devices do not raise any significant issues of safety or effectiveness.
7. SUMMARY OF NON-CLINICAL TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE
Non-clinical testing of the Callisyn FluidiTube® 2.7F Infusion Micro Catheter to demonstrate that the device met its specifications is summarized below.
Biocompatibility Evaluation
Biocompatibility testing is summarized in the table below. Testing was conducted according to the referenced methodology.
| Biocompatibility Evaluation and Extractables Testing | ||
|---|---|---|
| Test | Methodology | |
| Cytotoxicity | ISO 10993-5:2009 | |
| Irritation | ISO 10993-10:2010 | |
| Sensitization | ISO 10993-10:2010 | |
| Acute Systematic Injection | ISO 10993-11:2006 | |
| Materials Mediated Rabbit Pyrogen | USP | |
| Thrombosis (in vivo) | ISO 10993-4:2002 | |
| Hemolysis | ASTM F756-08 | |
| Complement Activation - C3a and SC5b-9 Assay | ISO 10993-4:2002 | |
| In vitro Mouse Lymphoma with Extended Treatment | ISO 10993-3:2003 | |
| In vivo Mouse Micronucleus Assay | ISO 10993-3:2003 | |
| ISO Bacterial Mutagenicity Test - Ames Assay | ISO 10993-3:2002 | |
| Extractables | ISO 10993-18:2005 |
Physicial and Mechanical Testing
Physical and mechanical testing is summarized below.
| Physical and Mechanical Testing | |
|---|---|
| • Kink resistance | • Static Pressure (Burst) |
| • Tensile (Catheter) | • Trackability |
| • Tensile (Hub-catheter) | • Flow Rate |
| • Reliability (Marker Band Durability) | • Size, OD and ID |
| • Coating Lubricity | • Hydrophillic Coating Coverage |
| • Corrosion Resistance | • Paticulate Testing |
| • Torqueability Testing | • Liquid and Air Leakage Testing |
| • Guidewire Compatibility | • Guide Catheter Compatibility |
In addition to the testing described above, the Callisyn FluidiTube® 2.7F Infusion Micro Catheter was also subject to shelf-life testing, packaging validation as per ISO 11607-1:2006, and simulated transport testing as per ISTA 2A:2011.
6
8. SUMMARY OF CLINICAL TESTING AS BASIS FOR SUBSTANTIAL EQUIVALENCE
Clinical testing was not conducted to evaluate substantial equivalence. Usability testing was conducted in an animal model under a simulated use environment to validate the performance of the device. Callisyn FluidiTube® 2.7F Infusion Micro Catheters were compared to Progreat® 2.7 F Microcatheters in a healthy male Yorkshire swine. Operators successfully tracked the microcatheters into the right artery, the hepatic arteries, and the contralateral iliac artery, and injected the representative diagnostic (non-ionic contrast media Omnipaque 300), therapeutic (Heparin), and embolic material (embolic microspheres 500-700μm) through each microcatheter into the hepatic arteries as required by the protocol. Both Operators rated all test and control microcatheters as acceptable for:
- . Ability to flush the packaging hoop and remove the microcatheter from the hoop without damage
- Ability to track the microcatheter through all three vessels and visualize them ● fluoroscopically
- Compatibility with the guidewire (0.014 in the RCA, 0.021 in the hepatic . artery, and 0.018 in the iliac artery)
- . Ability to visualize the device under fluoroscopy
- Compatibility 1mL of heparin, 2mL of non-dilute contrast media, and 1mL of ● 500-700um embolic microspheres when injected into the hepatic artery
- Integrity, with no kinking or damage to the tip ●
There was no damage to the catheters noted, no vascular dissection was observed, and no thrombus was observed on any catheter when removed from the animal.
After a thorough assessment of all test article performance features, including use in conjunction with common ancillary diagnostic and therapeutic products, both Operators determined that all study protocol specified acute performance requirements of the FluidiTube® were successfully met for this study and it is comparable to the Terumo Progreat® 2.7Fr Microcatheters predicate device.
9. CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL TESTS
The Indications for Use, overall design, technological and performance characteristics of the FluidiTube® and Progreat® are substantially equivalent. Based on the data and evidence presented (e.g., performance testing, simulated use testing, etc.) for the FluidiTube®, Callisyn concludes that the device is substantially equivalent to the legally marketed micro catheter for its intended use. Differences between the proposed and predicate device do not raise any new issues of safety or effectiveness.